Survival in a patient with polycythaemia vera for over thirty years: Implications for treatment decisions in younger patients

Leukemia and Lymphoma

Volumn 32, Issue 1-2, 1998, Pages 195-198

  Samuelsson, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Long term survival; Polycythaemia vera

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; CHLORAMBUCIL; HYDROXYUREA; PHOSPHORUS;

ACUTE LEUKEMIA; AGE; AGED; ARTICLE; CANCER SURVIVAL; CASE REPORT; FEMALE; HUMAN; MYELOPROLIFERATIVE DISORDER; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; THROMBOCYTOSIS;

EID: 0032458252     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809059262     Document Type: Article

References (29)

1. Kurita, S. (1974). Epidemiological studies of polycythemia vera in Japan. Acta Haematol Jpn, 37, 793-795.
2. Berglund, S. and Zetterwall, O. (1992). Incidence of polycythaemia vera in a defined population. Eur J Haematol, 48, 20-26.
3. Chaiter, Y., Brenner, B., Aghai, E., Tatarsky, I. (1992). High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk & Lymphoma, 7, 251-255.
4. Najean. Y., Mugnier, P., Dresch, C., Rain, J.D. (1989). Polycythemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol, 67, 285-291.
5. Chievitz, E. And Thiede, T. (1962). Complications and causes of death in polycythemia vera. Acta Med Scand, 172, 513-523.
6. Videbaek, A. (1950). Polycythemia vera. Course and prognosis. Acta Med Scand, 38, 179-187.
7. Iland, H.J., Laszlo, H., Case D.C. Jr., Murphy, S., Reichert, T.A., Tso, C.Y., Wasserman, L.R. (1987). Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis. Am J Hematol, 25, 191-201.
8. Berlin, N.I. (1976). Diagnosis and classification of the polycythemias. Semin Hematol, 12, 339-51.
9. Pearson, T.C. and Wetherley-Mein, G. (1978). Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet, 2, 1219-1222.
10. Berk, P.D., Goldberg, J.D., Silverstein, M., Weinfeld, A., Donovan, P.B., Ellis, J.T., Landaw, S.A., Laszlo, J., Najean, Y., Pisciota, A.V., Wasserman, L.R. (1981). Increased risk of acute leukaemia in polycythaemia vera associated with chlorambucil treatment. N Engl J Med, 304, 441-447.
11. Rozman, C, Giralt, M., Felihu, E., Rubio, D., Cortes, M.T. (1991). Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer, 63, 2658-63.
12. 32P between 1969 and 1981. Semin Hematol, 34, 6-16.
13. Berk, P.D., Goldberg, J.D., Donovan, P.D., Fruchtman, S.M., Berlin, N.I., Wassermann, L.R. (1986). Therapeutic recommendations in polycythemia vera based on the Polycythemia Vera Study Group protocols. Semin Hematol, 23, 132-143.
14. Landaw, S.A. (1986). Acute leukemia in polycythemia vera. Semin Hematol, 23, 156-165.
15. Stott, H., Fox, W., Girling, D.J., Stephens, R.J., Galton, G.A.D. (1977). Acute leukaemia after busulphan. Br Med J, 2, 1513-1517.
16. Weinfeld, A., Westin, J., Ridell, B., Swolin, B. (1977). Polycythemia vera terminating in acute leukemia. A clinical, cytogenetic and morphologic study in 8 patients treated with alkylating agents. Scand J Haematol, 19, 255-272.
17. Messinezy, M., Pearson, T.C., Prochazka, A., Wetherley-Mein G. (1985). Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one center. Br J Haematol, 61, 657-666.
18. Kaplan, M.E., Mack, K., Goldberg, J.D., Donovan, P.B., Berk, P.D., Wasserman, L.R. (1986). Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol, 23, 167-71.
19. Fruchtman, S.M., Mack, K., Kaplan, M.E., Peterson, P., Berk, P.D., Wasserman, L.R. (1997). From efficacy to safety: a polycythaemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol, 34, 17-23.
20. Nand, S., Messmore, H., Gross Fischer, S., Lourdes Bird, M., Sculz, W., Fischer, R.I. (1990). Leukemic transformation in polycythemia vera: analysis of risk factors. Am J Hematol, 34, 32-36.
21. 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood, 89, 2319-2327.
22. Najean, Y. and Rain, J.D. (1997). Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood, 90, 3370-3377.
23. Sterkers, Y., Preudhomme, C., Lai, J-L., Demory, J-L., Caulier, M-T., Wattel, E., Bordessoule, D., Bauters, F., Fenaux, P. (1998). Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high prportion of cases with 17p deletion. Blood, 91, 616-622.
24. Ludwig, H., Cortelezzi, A., van Kamp, B.G.K., Polli, E., Sheithauer, W., Kuzmits, R., Linkesch W, Gisslinger H, Sinzinger H, Fritz E, Flener R. (1985). Treatment with recombinant interferon-alpha-2c: multiple myeloma and thrombocythemia in myeloproliferative diseases. Oncology, 42 (suppl 1), 19-25.
25. Silver, R.T. (1990). A new treatment for polycythemia vera: recombinant interferon alfa. Blood, 76, 664-665.
26. Reilly, J.T., Vellenga, E., De Wolf, J.Th.M. (1996). Interferon treatment in polycythaemia vera. Leuk Lymphoma, 22, 143-148.
27. Hino, M., Futami, E., Okuno, S., Miki, T., Nishizawa, Y, Morii. (1993). Possible selective effect of Interferon α-2b on a malignant clone in a case of polycythemia vera. Ann Hematol, 66, 161-162.
28. Messora, C., Bensi, L., Vechi, A., Longo, R., Giacobbi, F., Temperani, P., Bevini, M., Emilia, G., Sacchi, S. (1994). Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol, 86, 402-404.
29. Anagrelide study group. (1992). Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients. Am J Med, 92, 69-76.